Cleo Diagnostics Locks in U.S. Billing Path Ahead of FDA Clearance
Cleo Diagnostics (ASX: COV) locks in U.S. reimbursement pathway ahead of FDA submission
Cleo Diagnostics Limited (ASX: COV) has outlined the first stage of its U.S. commercialisation and reimbursement strategy for its Pre-Surgical Ovarian Cancer Test, establishing a defined billing framework ahead of anticipated Food and Drug Administration (FDA) clearance. The company intends to enter the U.S. market immediately post-clearance under miscellaneous CPT code 81599, with reimbursement discussions anchored to comparable multi-biomarker tests, including OVA1, which have reported payer-dependent levels of approximately US$500–US$900 per test.
The framework operates as a two-stage pathway: the miscellaneous code enables immediate billing from the point of launch, while a subsequent application for a dedicated CPT code through the American Medical Association (AMA) CPT Editorial Panel targets consistent, standardised reimbursement at commercial scale.
When big ASX news breaks, our subscribers know first
What is a CPT code and why does it matter for diagnostic companies?
Current Procedural Terminology (CPT) codes are the universal billing language used across the U.S. healthcare system to identify and bill for medical procedures and diagnostic tests. Every laboratory test ordered and reimbursed in the U.S. requires a CPT code, making code assignment a foundational step for any diagnostic company seeking commercial revenue.
CPT code 81599 is a miscellaneous molecular pathology code that functions as the standard on-ramp for novel diagnostics. It allows a test to be billed on a case-by-case basis before sufficient clinical history exists to justify its own dedicated code. Reimbursement under 81599 is negotiated payer-by-payer, typically by cross-walking to comparable tests already in the market.
A dedicated CPT code, obtained through the AMA CPT Editorial Panel, represents the gold standard for commercial-scale diagnostic adoption. It delivers consistent, transparent reimbursement that is recognised broadly across payers and enables standardised utilisation tracking. For investors, this distinction is material: reimbursement access is widely regarded as the single biggest gating factor for diagnostic adoption in the U.S. By establishing this framework ahead of FDA clearance, CLEO removes a key commercialisation risk and shortens the window between regulatory approval and revenue generation.
What CPT code 81599 enables:
- Immediate post-FDA billing
- Early clinical prescribing across U.S. healthcare settings
- Real-world utilisation and economic evidence generation
- Pricing discussions with commercial and government payers
What a dedicated CPT code delivers (next stage):
- Consistent, transparent reimbursement
- Broader payer coverage and standardised tracking
- Long-term commercial scale for CLEO’s diagnostic platform
From FDA clearance to dedicated code — CLEO’s staged commercialisation timeline
Milestone sequence outlined
The announcement sets out a three-stage milestone sequence, with each phase building the clinical and economic evidence required to advance to the next.
| Milestone | Timing | What it unlocks for CLEO |
|---|---|---|
| Miscellaneous Code (81599) | Immediately post-FDA clearance | Early billing, clinical adoption, and real-world evidence generation |
| CPT Application Submission | ~6–12 months post-launch, aligned with next available AMA cycle | Formal application for a dedicated code backed by utilisation data |
| Dedicated CPT Code | Upon AMA clearance | Broader reimbursement coverage and scalable commercial adoption |
Supporting the transition — what CLEO is doing now
In parallel with its CPT 81599 launch preparation, CLEO is advancing three supporting activities designed to strengthen its eventual dedicated code application.
The company is progressing health economics and budget impact model development, which will quantify the clinical and cost value of earlier ovarian cancer detection. It is also strategically onboarding key opinion leaders to drive early clinical adoption, providing the prescribing base that generates real-world utilisation data. Finally, CLEO intends to capture real-world evidence through its initial commercial rollout under the miscellaneous code.
Together, these activities are designed to satisfy the AMA CPT Editorial Panel’s requirements for a dedicated code application — meaning the groundwork being laid now directly supports the transition to standardised, scalable reimbursement.
The next major ASX story will hit our subscribers first
Why this reimbursement milestone matters for CLEO investors
Ovarian cancer carries a 51% five-year mortality rate, the highest of all cancers affecting women, with late diagnosis identified as the primary driver. CLEO’s Pre-Surgical Ovarian Cancer Test addresses this unmet need directly, and the commercial opportunity depends significantly on how quickly the company can generate revenue post-clearance.
This reimbursement milestone addresses that question concretely. CLEO will not be waiting for a billing framework after FDA clearance — it already has one. The availability of CPT code 81599 means the company can commence case-by-case billing from launch, with payer discussions supported by a comparator range of approximately US$500–US$900 per test based on existing multi-biomarker assays including OVA1. This figure is payer-dependent and reflects comparator pricing, not a confirmed CLEO-specific reimbursement rate.
The underlying technology adds further context to the commercial case. CLEO’s CXCL10 biomarker platform is supported by more than 15 years of scientific research and development, with a pivotal clinical trial currently underway and FDA submission anticipated. The biomarker is reported to be produced early and at high levels in ovarian cancer while remaining largely absent in benign disease, positioning it as a strong discriminator between malignant and non-malignant findings.
The staged logic of the commercialisation pathway reinforces investor confidence at each step: the miscellaneous code enables early revenue and evidence generation, that evidence supports the dedicated CPT code application, and a dedicated code unlocks broader payer coverage and long-term commercial scale. Each milestone de-risks the next.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news and in-depth analysis directly to your inbox within minutes of release. Over 20,000 active subscribers are already getting the full picture the moment announcements hit. Click the “Free Alerts” button to stay ahead of market-moving developments across ASX healthcare and beyond.